# Eximo Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/eximo-medical

- Industry: Medical Devices & Equipment
- Headquarters: Rehovot, Israel
- Website: www.eximomedical.com
- Total disclosed funding: $1.6M
- Latest round: Series A (Jul 29, 2015)
- Investors on record: 2

## About

Eximo Medical Ltd. develops innovative medical technologies focused on improving treatment options for peripheral arterial disease. Their flagship product is aimed at enhancing patient outcomes through effective vascular interventions.Eximo Medical Ltd. specializes in medical technology, particularly in the field of peripheral atherectomy treatment. Founded in 2011 and headquartered in Rehovot, Israel, the company has successfully completed 5 funding rounds. Led by CEO Yoel Zabar, Eximo Medical raised USD 46.00 mn in a TRADE SALE round from AngioDynamics, Inc., which represents the total amount raised to date.Eximo Medical Ltd. focuses on advanced medical technology, with their key product being the Auryon System. This system is designed for peripheral atherectomy treatment, addressing various lesions, including in-stent restenosis (ISR). The Auryon System simplifies the treatment process for patients with peripheral arterial disease (PAD) and has shown effectiveness in clinical trials by reducing plaque burden and achieving high patency rates across multiple lesion types. The company serves hospitals, outpatient surgical centers, and healthcare providers primarily in North America, Europe, and select Asian markets.Eximo Medical Ltd. generates revenue through the direct sales of its medical devices, particularly the Auryon System and its associated catheters. The company engages in B2B transactions with healthcare facilities, providing essential equipment for vascular interventions tailored to meet the specific needs and procedural requirements of healthcare providers.Eximo Medical Ltd. is focused on expanding its product line, with new products currently in development aimed at enhancing vascular treatment options. The company plans to enter new geographic markets, targeting expansion in Europe and Asia by 2025. Recent funding will be utilized to support these growth initiatives, including product development and market entry strategies.

## Funding rounds

- Series A, Jul 29, 2015, $1.6M — Technion Research & Development Foundation, Accelmed

## Investors

- Technion Research & Development Foundation — Series A
- Accelmed (https://capitalatlas.ai/funds/accelmed) — Series A